Insights on UpScriptHealth’s Recent Pfizer Partnership & Its Impact on Drug Access

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry, highlighting that tariffs will initially affect pharmaceutical companies, particularly those dealing with branded medications and generics. He notes that tariffs could lead to strategic supply chain changes, including potential US manufacturing shifts. Digital health platforms like UpScriptHealth aim to reduce friction and costs in healthcare, potentially offsetting tariff impacts. Ax emphasizes the importance of telehealth in ensuring medication availability and the strategic partnerships between digital health platforms and pharma companies to improve patient care and access. He also praises Pfizer's approach to delivering comprehensive care rather than just selling medications.

Can you share insights on how your recently partnership with Pfizer is helping to navigate current challenges in drug pricing and delivery, and how it might be relevant in a scenario with increased tariffs?

I can't speak for Pfizer, but I can tell you my view is that Pfizer has made a strategic decision to be a part of the solution for the problems in healthcare. It's not about selling a medication specifically to a patient, or it’s a lot about delivering care that that they can help solve the patient's problem. And that might mean that the patient is prescribed their drug. It might mean that the patient is prescribed 10 other drugs, but they're going to provide a mechanism that patients can access care and receive great treatment. And if you think about PfizerForAll, they're not focused in on the brand strategy down below where you're kind of looking at specific medications. They're focused on ‘Let's treat migraine headaches’, ‘Let's treat respiratory illnesses, including COVID’, ‘Let's treat whatever category of disease they want to treat’, and let's just be sure that we're helping patients get great access to care. I give Pfizer enormous credit for their approach to this, to this problem.